What Alzheimer’s Medications Are Currently FDA-Approved?

Learn which symptom drugs and early-stage amyloid treatments fit your situation and what to ask your doctor.

Currently FDA-approved Alzheimer's medications are donepezil, rivastigmine, galantamine, memantine, lecanemab (Leqembi), and donanemab (Kisunla). The first four help manage symptoms, while lecanemab and donanemab target amyloid buildup in early symptomatic disease. Alzheimer's disease slowly damages memory, thinking, and daily function.

Treatment now falls into two groups: daily symptom drugs and amyloid-directed antibodies that require careful patient selection. Aducanumab (Aduhelm) is no longer a current option after its approval was withdrawn effective Nov. 1, 2024.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Drugs that support memory symptoms

Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors for mild-to-moderate symptoms. According to the Alzheimer's Association, they preserve acetylcholine in current medications guide current medications guide. Acetylcholine is a brain chemical that carries memory signals between nerve cells.

These drugs do not stop the underlying disease process. They may help attention, recall, and daily tasks for a time. Families often discuss timing, response, and side effects with the prescribing clinician.

Options for moderate-to-severe symptoms

Memantine is an NMDA-receptor antagonist approved for moderate-to-severe Alzheimer's. NMDA refers to a brain receptor system involved in learning and memory. The drug helps regulate abnormal brain signaling tied to later-stage symptoms.

It is also sold in a memantine plus donepezil combination for later-stage symptoms. That combination can simplify dosing when both drugs are prescribed. Clinicians match the choice to stage, tolerance, and care goals.

What makes Leqembi and Kisunla different

Leqembi (lecanemab-irmb) is an amyloid-beta-directed antibody for Alzheimer's. The U.S. FDA gave accelerated approval on Jan. 6, 2023 in its accelerated approval announcement.

It was the second drug in that mechanistic class. The FDA converted Leqembi to traditional approval on July 6, 2023 after a confirmatory trial verified benefit in early disease. Kisunla (donanemab-azbt) was approved on July 2, 2024 for adults with Alzheimer's. The FDA noted Fast Track, Priority Review, and Breakthrough Therapy designations in its approval notice for Kisunla.

Who can receive amyloid antibody treatment

Leqembi and Kisunla are only for early symptomatic disease with confirmed amyloid pathology. Amyloid pathology means abnormal protein buildup linked to Alzheimer's. Use requires biomarker testing and careful patient selection, not treatment at all stages.

Both drugs carry FDA boxed warnings for amyloid-related imaging abnormalities, called ARIA. ARIA means brain swelling or small bleeds seen on scans. According to FDA safety information, treatment requires MRI monitoring and caution with blood thinners in its drug-safety update on MRI monitoring. Readers considering referral can check these practical points: Ask the memory clinic what tests confirm eligibility and how MRI visits are scheduled.

  • symptoms are early, with mild cognitive impairment or mild dementia
  • amyloid buildup is confirmed by PET scan or spinal-fluid test
  • recent brain MRI and medication review are complete
  • regular MRI visits and follow-up care are possible

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.